Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Working Capital Changes (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Other Working Capital Changes for 3 consecutive years, with -$42000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Working Capital Changes fell 108.61% year-over-year to -$42000.0, compared with a TTM value of -$14000.0 through Dec 2024, up 98.36%, and an annual FY2024 reading of -$14000.0, up 98.36% over the prior year.
  • Other Working Capital Changes was -$42000.0 for Q4 2024 at Oramed Pharmaceuticals, down from $23000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $488000.0 in Q4 2023 and bottomed at -$1.4 million in Q2 2023.
  • Average Other Working Capital Changes over 3 years is -$142636.4, with a median of $23000.0 recorded in 2024.
  • The sharpest move saw Other Working Capital Changes soared 105.11% in 2023, then crashed 205.88% in 2024.
  • Year by year, Other Working Capital Changes stood at $331000.0 in 2022, then surged by 47.43% to $488000.0 in 2023, then tumbled by 108.61% to -$42000.0 in 2024.
  • Business Quant data shows Other Working Capital Changes for ORMP at -$42000.0 in Q4 2024, $23000.0 in Q3 2024, and $41000.0 in Q2 2024.